BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 16256792)

  • 21. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression.
    Pulling LC; Divine KK; Klinge DM; Gilliland FD; Kang T; Schwartz AG; Bocklage TJ; Belinsky SA
    Cancer Res; 2003 Aug; 63(16):4842-8. PubMed ID: 12941804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of O6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphomas.
    Lee SM; Lee EJ; Ko YH; Lee SH; Maeng L; Kim KM
    APMIS; 2009 Feb; 117(2):87-94. PubMed ID: 19239430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma.
    Hou P; Ji M; Yang B; Chen Z; Qiu J; Shi X; Lu Z
    Cancer; 2006 Apr; 106(7):1602-9. PubMed ID: 16502411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer.
    Kim H; Kwon YM; Kim JS; Han J; Shim YM; Park J; Kim DH
    Cancer; 2006 Sep; 107(5):1042-9. PubMed ID: 16888795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma.
    Belinsky SA; Klinge DM; Liechty KC; March TH; Kang T; Gilliland FD; Sotnic N; Adamova G; Rusinova G; Telnov V
    Carcinogenesis; 2004 Jun; 25(6):1063-7. PubMed ID: 14742312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung.
    Licchesi JD; Westra WH; Hooker CM; Herman JG
    Clin Cancer Res; 2008 May; 14(9):2570-8. PubMed ID: 18451218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
    Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma.
    Ksiaa F; Ziadi S; Amara K; Korbi S; Trimeche M
    Clin Chim Acta; 2009 Jun; 404(2):128-33. PubMed ID: 19336228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma.
    Tanaka R; Wang D; Morishita Y; Inadome Y; Minami Y; Iijima T; Fukai S; Goya T; Noguchi M
    Cancer; 2005 Feb; 103(3):608-15. PubMed ID: 15612080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promoter hypermethylation of the p16 gene is associated with poor prognosis in recurrent early-stage hepatocellular carcinoma.
    Ko E; Kim Y; Kim SJ; Joh JW; Song S; Park CK; Park J; Kim DH
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2260-7. PubMed ID: 18723830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.
    Schildhaus HU; Kröckel I; Lippert H; Malfertheiner P; Roessner A; Schneider-Stock R
    Int J Oncol; 2005 Jun; 26(6):1493-500. PubMed ID: 15870861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
    Esteller M; Sanchez-Cespedes M; Rosell R; Sidransky D; Baylin SB; Herman JG
    Cancer Res; 1999 Jan; 59(1):67-70. PubMed ID: 9892187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
    Kikuchi S; Yamada D; Fukami T; Maruyama T; Ito A; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Cancer; 2006 Apr; 106(8):1751-8. PubMed ID: 16534787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
    Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
    Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers.
    Arai T; Miyoshi Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2006 Nov; 100(2):169-76. PubMed ID: 16791478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
    Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
    Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma.
    Enokida H; Shiina H; Urakami S; Terashima M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Igawa M; Dahiya R
    Cancer; 2006 Jan; 106(1):79-86. PubMed ID: 16323173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
    Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
    Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.